Table 2 Public procurement of antineoplastic agents used for treating breast cancer - total spending (R$) by purchaser category. Brazil, 2013–2019

Anastrozole 1 mg^a

13,196,020

39.67

9,337,267

28.07

5,263,653

15.83

5,464,512

16.43

33,261,452

Docetaxel 40 mg^b

22,886,244

38.63

19,535,557

32.97

6,095,049

10.29

10,729,355

18.11

59,246,205

Exemestane 25 mg^c

16,301,476

50.07

4,857,270

14.92

6,449,958

19.81

4,948,653

15.20

32,557,358

Letrozole 2.5 mg^a

6,683,805

56.11

573,524

4.81

3,549,046

29.79

1,105,916

9.28

11,912,291

Paclitaxel 6 mg^b

26,010,194

57.78

8,515,488

18.92

4,896,219

10.88

5,591,795

12.42

45,013,696

Tamoxifen 20 mg^a

19,865,277

54.79

9,197,183

25.37

1,604,663

4.43

5,589,036

15.42

36,256,160

Trastuzumab 440 mg^b

79,911,241

10.86

195,836,172

26.62

174,182,648

23.68

285,744,659

38.84

735,674,721

Vinorelbine 10 mg^d

6,305,699

57.00

2,153,148

19.46

814,825

7.37

1,788,105

16.16

11,061,777

Vinorelbine 20 mg^d

6,338,358

40.90

6,429,645

41.49

2,498,773

16.13

228,920

1.48

15,495,696

Vinorelbine 30 mg^d

17,960,731

56.49

9,193,434

28.92

4,351,541

13.69

286,020

0.90

31,791,725

Total

215,459,045

21.28

265,628,688

26.24

209,706,375

20.72

321,476,971

31.76

1,012,271,080